[SCHEDULE 13G/A] Stoke Therapeutics, Inc. Amended Passive Investment Disclosure
FMR reports 9.8% stake in Stoke Therapeutics
FMR LLC and Abigail P. Johnson reported a significant ownership position in Stoke Therapeutics, Inc.December 31, 20255,600,920 shares9.8% FMR LLC has sole voting power over 5,590,109 shares5,600,920 shares
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
FMR LLC and Abigail P. Johnson reported a significant ownership position in Stoke Therapeutics, Inc.December 31, 20255,600,920 shares9.8%
FMR LLC has sole voting power over 5,590,109 shares5,600,920 shares
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake did FMR LLC report in Stoke Therapeutics (STOK)?
FMR LLC reported beneficial ownership of 5,600,920 shares of Stoke Therapeutics common stock, representing 9.8% of the outstanding class. This indicates FMR holds a sizable institutional position in the company as of December 31, 2025, based on Schedule 13G/A disclosure.
What role does Abigail P. Johnson have in the Stoke Therapeutics (STOK) holdings?
Abigail P. Johnson is reported as a beneficial owner of 5,600,920 Stoke Therapeutics shares with sole dispositive power. She is identified separately from FMR LLC, reflecting her control-person status over these holdings while reporting no sole or shared voting power in the filing.
What voting and dispositive powers did FMR LLC report over STOK shares?
FMR LLC reported sole voting power over 5,590,109 Stoke Therapeutics shares and sole dispositive power over 5,600,920 shares. It reported zero shared voting or shared dispositive power, indicating centralized control of voting and sale decisions within the FMR complex for these securities.
Is FMR LLC seeking to influence control of Stoke Therapeutics (STOK)?
The filing states the securities were acquired and are held in the ordinary course of business, not for changing or influencing control of Stoke Therapeutics. It also notes they are not held in connection with any transaction having that purpose, aside from activities tied to certain nomination rules.
Do other investors benefit from FMR LLC’s Stoke Therapeutics (STOK) position?
The filing notes one or more other persons may have rights to dividends or sale proceeds from Stoke Therapeutics common stock held by FMR-related entities. However, no single such person is described as having an interest exceeding five percent of the total outstanding common stock.
What is the key date referenced in this Stoke Therapeutics (STOK) Schedule 13G/A?
The key event date in the Schedule 13G/A is December 31, 2025. Ownership figures, including the 5,600,920 shares and the 9.8% of class reported by FMR LLC and Abigail P. Johnson, are stated as of that date for Stoke Therapeutics common stock.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
STOKE THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
86150R107
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
86150R107
1
Names of Reporting Persons
FMR LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
5,590,109.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
5,600,920.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,600,920.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.8 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP No.
86150R107
1
Names of Reporting Persons
Abigail P. Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
5,600,920.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,600,920.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.8 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
STOKE THERAPEUTICS INC
(b)
Address of issuer's principal executive offices:
45 WIGGINS AVENUE,BEDFORD,MA,USA,01730
Item 2.
(a)
Name of person filing:
FMR LLC
(b)
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
86150R107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
5600920.00
(b)
Percent of class:
9.8 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
5600920.00
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of STOKE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of STOKE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
02/04/2026
Abigail P. Johnson
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:
02/04/2026
Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
